Perspective
Featured Topics
Lead story
Other featured articles
-
Medicare’s Mental Health Care Problem
Mental health care providers are subject to unique constraints and incentives, compared to other specialists.
Posted in -
Knowing Actual Prices Will Help HHS Set the Maximum Fair Price under the Inflation Reduction Act
Requiring data on actual net costs will improve negotiations over the “maximum fair price” for select drugs under Medicare.
Posted in -
Response to Sen. Cassidy’s Request for Information on Improving Americans’ Access to Gene Therapies
Schaeffer experts submitted a comment letter responding to a request for information from stakeholders about improving access to cell and gene therapies for ultra-rare diseases.
Posted in -
Does Medicare Advantage Deliver Better Care for Persons Living with Dementia than Traditional Medicare?
With data available from CMS on all Medicare beneficiaries enrolled in private plans and traditional Medicare, researchers at the USC Schaeffer Center are driving new research on how payment structures impact the care of persons living with dementia.
Posted in
ADDITIONAL Perspectives
-
The Inflation Reduction Act’s Harms Go Beyond Drug Pricing — They’re Threatening Your Medicare
The IRA threatens to deliver disaster across the entire innovation, financing and distribution system for prescription drugs.
Categorized in -
Can a Free Virtual Outreach Series Increase Alzheimer’s Disease Awareness?
Lack of awareness remains one of the biggest barriers to participation in Alzheimer’s disease clinical trials, especially among underrepresented groups. New ways to connect with communities and to expand access to clinical trials include a virtual Alzheimer’s disease informational series, which reveals important insights about how people engage with virtual content differently than at in-person events.
Categorized in -
Biden’s Hepatitis C Initiative Needs Help from the Private Market
Instead of this massive nationalized program, the White House could make four administrative changes that would jump-start private-sector solutions in each state.
Categorized in -
Want Lower Obesity Drug Costs? Medicare Holds the Key
Medicare coverage will catalyze market competition
Categorized in -
Comments on CBO Blog Post: “A Call for New Research in the Area of Obesity”
While there are significant data and methodological challenges to be overcome, there are better alternatives to simplistically extrapolating from the real-world data on AOM use that is currently available.
Categorized in -
How the Secrecy of Middlemen Inflates Drug Prices
Drug costs can be driven down if market forces are allowed to target those profits, but first everyone needs to know what is being charged, and by whom to whom.
Categorized in